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ABSTRACT OF THE DISSERTATION
DEVELOPING TRIAGE TOOLS FOR RETENTION IN CARE AND VIRAL
SUPPRESSION, AND IDENTIFYING PREDICTORS OF SEXUALLY
TRANSMITTED INFECTIONS AMONG PEOPLE WITH HIV
by
Merhawi Teklezgi Gebrezgi
Florida International University, 2020
Miami, Florida
Professor Mary Jo Trepka, Major Professor
This study developed risk prediction tools for non-retention in HIV care and nonviral suppression, and identified factors associated with self-reported chlamydia and
gonorrhea diagnosis among people with HIV (PHIV) in the Miami-Dade County Ryan
White Program (RWP). Using retrospective cohort study data, we used stepwise logistic
regression to develop score-based risk prediction tools for non-retention in care and nonviral suppression. We then used bootstrapping to internally validate the risk prediction
tools. We also assessed the prevalence of self-reported chlamydia and gonorrhea
diagnoses and factors associated with the diagnoses cross-sectionally using multivariate
logistic regression.
Among the 7439 people meeting the inclusion criteria for the retention analysis,
we found that non-retention in care in the next year could be predicted using current age,
race, poverty level, homelessness, problematic alcohol/drug use and viral suppression
status. The risk prediction tool had low discrimination (c-statistic=0.65), and the total
score ranged from 0 to 17. Among the 6492 people meeting the inclusion criteria for the
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viral suppression analysis, non-viral suppression in the next year could be predicted using
current age, race, poverty level, AIDS status, homelessness, problematic alcohol/drug use
and current viral suppression status. The risk prediction tool for non-viral suppression
had good discrimination (c-statistic=0.77), and the total score ranged from 0 to 26.
Of the 7,419 adult PHIV in active Ryan White care during 2017, about half (n=
3528) reported being screened for chlamydia or gonorrhea during 2017. Of these, 2.3%
reported having been diagnosed with chlamydia or gonorrhea or both in 2017. Having a
chlamydia or gonorrhea diagnosis was associated with being in the age group 18–39 and
having multiple sexual partners during the previous 12 months.
In conclusion, using routinely available variables, we developed risk prediction
tools for non-retention in care and non-viral suppression that can assist healthcare
providers in identifying high-risk individuals to target for intervention. Both risk
prediction tools need external validation. The risk prediction tool for non-retention in
care additionally needs to include more prognostic factors in order to increase the
discrimination. In order to prevent chlamydia or gonorrhea, targeted behavioral risk
reduction techniques are highly recommended among those 18–39 years of age and those
who have multiple sexual partners.
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INTRODUCTION
Since the start of the human immunodeficiency virus (HIV) epidemic, about 75
million people have been infected with HIV (WHO, 2019; UNAIDS, 2019). Globally, by
the end of 2018, there were approximately 39.9 million people living with HIV; and in
the same year, 770,000 people died from HIV-related illnesses and 1.7 million people
became newly infected with HIV (WHO, 2019; UNAIDS, 2019). In the United States, at
the end of 2015, around 1.1 million people were living with HIV (Centers for Diseases
Control and Prevention, 2018). Within the U.S., in 2017, Florida had the highest number
of estimated new HIV infections followed by California and Texas (CDC, 2019(a)). In
2017, there were a total of 116,944 people with HIV (PHIV) in Florida (Florida
Department of Health 2018 (a)).
Once diagnosed with HIV, PHIV need to be linked to care, take antiretroviral
therapy (ART) and adhere to their medications to achieve successful HIV care outcomes.
The HIV care continuum, also known as the HIV treatment cascade, includes a
sequence of steps from initial diagnosis to achieving viral suppression. These steps are
diagnosis of HIV infection, linkage to HIV care, retention in HIV care, adherence to
ART, and viral suppression (U.S. Department of Health & Human Services, 2016).
Retention in HIV care is a key step in ART adherence and viral suppression. Viral
suppression (i.e. amount of HIV in the body is very low or undetectable) is the final and
ultimate goal of the HIV care continuum and is usually a reflection of success in HIV
care. It is important to monitor the proportion of PHIV engaged in each stage of the HIV
care continuum, to help policymakers to identify the gaps and implement system
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improvements and service enhancements that better support individuals as they move
from one stage in the continuum to the next (U.S. Department of Health & Human
Services, 2016).
Viral suppression (low viral load) benefits the individual living with HIV and the
community. Virally suppressed individuals have slower disease progression, increased
survival (Lima et al., 2007, Montaner 2011; Samji et al., 2013), and reduced risky sexual
behavior (Mattson et al., 2014). At a community level, virally suppressed individuals are
less likely to transmit the virus to others (Philbin et al., 2014; Cohen et al., 2011; Shah et
al., 2016). Persons who are HIV infected but undiagnosed and persons who are HIV
diagnosed but not retained in medical care were responsible for 91.5% of the estimated
HIV transmissions in 2009 (Skarbinski et al., 2015). Therefore, by ensuring that everyone
with HIV is aware of their infection and achieving viral suppression, HIV infections can
be reduced.
In 2017, in the United States and six dependent areas, 86% of people living with
HIV knew their status, 63% received medical care, 49% were retained in care and 51%
were virally suppressed (Centers for Diseases Control and Prevention, 2017). The
National HIV/AIDS Strategy 2020 aims to increase the number of HIV-positive
individuals aware of their status to 90%, the proportion of persons with newly diagnosed
HIV who are linked to care within one month to 85%, and the proportion of HIVdiagnosed individuals whose virus is effectively suppressed to 80% (CDC 2019(b)). Of
all people living with HIV in Florida in 2017, 68% were retained in care (defined as
having two or more documented viral load/CD4 laboratory results, medical visits or
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prescription, at least three months apart in 2017) and 62% were virally suppressed
(defined as a viral load <200copies/mL on the last viral load test in 2017) (Florida
Department of Health 2018 (a)). In Miami-Dade County, of all people living with HIV in
2017, 64% were retained in care and 58% were virally suppressed (Florida Department of
Health 2018 (b)).
Previous studies have found individual, social, behavioral and community factors
associated with retention in care and viral suppression (Woodward et al., 2015; Bengtson
et al., 2016; Giordano et al., 2009; Lourenço et al., 2014; Nosyk et al., 2015; Rebeiro et
al., 2013; Tedaldi et al., 2014; Giordano, 2011; Robbins et al., 2010; Whiteside et al.,
2014; Crepaz et al., 2018; Sheehan et al., 2017; Geter et al., 2018; Castel et al., 2016;
Muthulingam et al., 2013; Tanner et al., 2016; Blank et al., 2015; Myers et al., 2016; Beer
et al., 2016). These findings are amenable to being translated into validated and easy-touse risk prediction tools to predict an individual’s risk of not being retained in HIV care,
or not achieving viral suppression (McNairy et al., 2017). Risk prediction tools are
developed to identify patients at risk and to facilitate decision making. Factors to be
included in the risk prediction tool should be routinely collected information, available to
healthcare providers across diverse healthcare settings. Therefore, we used routinely
collected sociodemographic, clinical, and laboratory information such as age, sex,
race/ethnicity, alcohol/drug use, income level, living arrangement, transportation and
food needs, acquired immunodeficiency syndrome (AIDS) status, initial viral loads, and
other information to develop the risk prediction tool.
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In addition to the type of exposure (such as blood transfusion), behavior (such as
sharing needles or having sex without a condom), and high viral load (unsuppressed viral
load), sexually transmitted infections (STIs) increase the risk of HIV transmission,
(Centers for Diseases Control and Prevention, 2019 (c)). Sexually transmitted infections
among PHIV increase HIV transmission through effects on HIV replication, HIV
shedding, increases in viral diversity and through co-transmission of HIV with STIs
(Galvin and Cohen 2004). Sexually transmitted infections among HIV-seronegative
individuals also increase HIV susceptibility by mucosal disruption, immune changes in
the genital tract, and effects on the genital tract microenvironment (Galvin and Cohen,
2004). The Centers for Diseases Control and Prevention (CDC) recommends annual STI
screening among sexually active PHIV (Workowski &amp; Bolan, 2015). Despite this
recommendation, the rate of STIs screening among PHIV is suboptimal (Flagg et al.,
2015; Quilter et al., 2017). Therefore, screening and monitoring for STIs among PHIV is
an important standard of care in order to reduce HIV transmission.
The overall objectives of this dissertation were to develop a risk tool for retention
in care, to develop a risk tool for viral suppression, and to identify predictors of sexually
transmitted diseases among PHIV. In order to achieve this objective, we conducted three
separate studies. The first study aimed to develop a risk prediction tool to identify people
living with HIV who are at risk for non-retention in care. The second study aimed to
develop a risk prediction tool to identify people living with HIV who are at risk of nonviral suppression. The third study aimed to identify predictors of chlamydia or gonorrhea
diagnoses among PHIV. The first and second objectives address fundamental questions in
the HIV care continuum by providing health care providers with risk prediction tools. By
4

using these tools, health care providers can predict individual’s probability of falling out
of HIV care or failing to achieve viral suppression in next year. If people likely to fall out
of HIV care or to fail to achieve viral suppression are identified early, these people could
be offered additional services to help them achieve retention and viral suppression. The
third objective aimed to identify the main sociodemographic, behavioral and clinical
predictors of chlamydia or gonorrhea diagnoses among PHIV. Understanding these
factors can assist healthcare providers in their efforts to design interventions for PHIV
who are at risk of developing these STIs. Ultimately, the results from this dissertation can
improve client’s retention, viral suppression, and STIs risk, and ultimately improve the
quality of life of PHIV.
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MANUSCRIPT 1
Gebrezgi M.T., Fennie K.P., Sheehan D.M., … & Trepka MJ. (2020). Developing a
triage tool for use in identifying people living with HIV who are at risk for non-retention
in HIV care. Int J STD AIDS. In press.
Abstract
Introduction: Identifying PHIV in HIV care who are at particular risk of non-retention
in care is an important element in improving their HIV care outcomes. The purpose of
this study was to develop a risk prediction tool to identify PHIV at risk of non-retention
in care over the course of the next year.
Methods: We used stepwise logistic regression to assess sociodemographic, clinical and
behavioral predictors of non-retention in HIV care. Retention in care was defined as
having evidence of at least two encounters with an HIV care provider (or CD4 or viral
load lab tests as a proxy measure for the encounter), at least 3 months apart within a year.
We validated the risk prediction tool internally using the bootstrap method.
Results: The risk prediction tool included a total of six factors: age group, race, poverty
level, homelessness, problematic alcohol/drug use, and viral suppression status. The total
risk score ranged from 0 to 17. Compared to those in the lowest quartile (0 risk score),
those who were in the middle two quartiles (score 1–4) and those in the upper quartile
(>4 risk score) were more likely not to be retained in care (odds ratio [OR] 1.63 [CI;
1.39−1.92] and OR 4.82 [CI; 4.04−5.78] respectively). The discrimination ability for the
prediction model was 0.651.
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Conclusions: We found that increased risk for non-retention in care can be predicted
with routinely available variables. Since the discrimination of the tool was low, future
studies may need to include more prognostic factors in the risk prediction tool.
Keywords: non-retention, HIV, AIDS, risk prediction tool, risk score
Introduction
The navigation of people with HIV (PHIV) across the HIV care continuum
includes being diagnosed with HIV, linked to care, engaged in care, retained in care,
adherent to antiretroviral therapy (ART), and having a suppressed HIV viral load (Kay et
al., 2016). A goal of the United States (US) National HIV/AIDS Strategy is to increase
the percentage of persons with diagnosed HIV who are retained in HIV medical care to at
least 90 percent by 2020 (U.S. Department of Health & Human Services, 2015). The
Centers for Diseases Prevention and Control (CDC) monitors retention in care using
laboratory data from jurisdictions with complete reporting of CD4 and viral load test
results. In 2015, only 57.2% of PHIV were retained in care (Centers for Disease Control
and Prevention, 2019). Among 38 states with complete lab reporting for 2015 and 2016,
none met the National HIV/AIDS Strategy 2020 target of 90%, 21 made progress toward
the 2020 target, and 17 made no progress (Centers for Disease Control and Prevention,
2019).
Factors related to demographics, behavior, psychosocial and physical health affect
retention in HIV care (Bulsara et al., 2016). Those factors include substance use
(Giordano et al., 2009; Dombrowski et al., 2015; Centers for Diseases Control and
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Prevention, 2018), belonging to a racial ethnic minority group (Giordano et al., 2009;
Rebeiro et al., 2013; Giordano, 2011), mental health problems (Dombrowski et al., 2015;
Centers for Diseases Control and Prevention, 2018), young age (Giordano et al., 2009;
Nosyk et al., 2015; Lourenço et al., 2014; Tripathi et al., 2011), female gender (Giordano,
2011; Lourenço et al., 2014), injection drug use (IDU) as the vector for infection
(Rebeiro et al., 2013; Giordano, 2011; Nosyk et al., 2015), having public health insurance
(Tedaldi et al., 2014), health literacy (Waldrop-Valverde et al., 2013), intimate partner
violence) Schafer et al., 2012), low socioeconomic status (Centers for Diseases Control
and Prevention, 2018; Giordano, 2011), past-year missed treatment visits (Pence et al.,
2018) and greater unmet socioeconomic needs such as housing, food, or transportation
(Centers for Diseases Control and Prevention, 2018; Giordano, 2011). Some studies have
synthesized these factors and devised a risk prediction tool to identify people who might
be poorly retained in HIV care. A study attempted to develop a clinical decision tool to
estimate the probability of being lost to follow-up among adults initiating antiretroviral
therapy in resource-limited settings (McNairy et al., 2018). The study found that young
age and advanced WHO disease stage were significant predictors of being lost to followup, but the model had weak ability to discriminate those who will remain in care from
those who will be lost to follow-up. Another study developed a risk score to identify
HIV-infected women who are most likely to be lost to follow-up in the postpartum period
(Bengtson et al., 2016). Parity, education, employment status, WHO clinical stage,
duration of combination ART during pregnancy, and number of antenatal care visits were
found to predict being lost to follow-up. Woodward and his colleagues developed a risk
prediction tool for medical appointment attendance among HIV-infected persons with
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unsuppressed viremia (Woodward et al., 2015). They found that active substance abuse,
poor adherence to daily medications, history of missing HIV care appointments, prior
treatment failure, prior exposure to ART (defined as any prior exposure to nucleot(s)ide
reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, and
protease inhibitor classes OR a current regimen containing enfuvirtide), most recent CD4
lymphocyte count < 100 copies/mm3, and most recent viral load > 200 copies/mL
predicted poor medical appointment attendance (Woodward et al., 2015).
Poor retention in care can lead to undesirable HIV outcomes at the individual and
population levels (Giordano, 2011). Poor retention in care has been found to be
associated with higher viral loads, lower CD4 cell counts (Tripathi et al., 2011), higher
rates of ART failure, decreased likelihood of receiving antiretroviral therapy, increased
HIV transmission risk behavior, increased hospitalization rates, and worse survival
(Giordano, 2011). Therefore, retention in HIV care is a key step to improve HIV
outcomes and overall health of PHIV. The aim of this study was to identify people in
HIV care who are likely to be poorly retained in care over the course of the following
year using sociodemographic, clinical, and laboratory information.
Methods
We used retrospective data from the Miami-Dade County (Florida) Ryan White
Program (RWP) Part A/ Minority AIDS Initiative (MAI) for the calendar years 2016–
2017 to assess the relationship between sociodemographic, clinical and behavioral
variables and risk of non-retention in HIV care, with a primary focus on routinely
available variables. The RWP Part A provides core medical, medical case management,
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pharmaceutical, and related support services to low-income people with HIV in
metropolitan areas heavily impacted by HIV/AIDS (“Eligible Metropolitan Areas,” or
EMAs), to improve their access to HIV care and their health outcomes; the MAI program
provides additional support for a subset of these services, targeted toward ethnic and
racial minorities in these EMAs.
Study population
The population was PHIV who were enrolled in (and receiving services from) the
RWP Part A/MAI program in the Miami-Dade EMA in 2016. Enrollment was defined as
having received at least one medical case management encounter or peer education
support network service in 2016. We measured risk factors in 2016, and the outcome
(non-retention in care) was measured in 2017. Risk factors were obtained from the
RWP’s comprehensive health assessment, patient intake assessment and laboratory
results entered into the patient’s electronic medical records. The comprehensive health
assessment is a health and social needs assessment of RWP patients that is completed
every 6 months to determine the plan of care and needs for referrals to other services.
Patient intake assessment includes demographic data collected at time of entry into the
RWP. We excluded people who had no comprehensive health assessment in 2016, or
were <18 years old in January 2016, who died in 2016 or 2017, or were out-of-network
referrals in 2016 or 2017. Out-of-network referrals are people who were referred to the
RWP from a non-RWP provider, receiving a single service but not receiving regular
medical case management, and for whom data about retention would not be available.
We also excluded clients if their case was closed because of movement to another
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state/county, financial ineligibility, or incarceration greater than 6 months in 2016 and
2017. Moreover, clients diagnosed with HIV in 2016, and those who received their first
RWP care in 2016 but who had no viral load measurement in 2016 were excluded from
the analysis. We deleted four people who had missing information about problematic
alcohol/drug use in 2016.
Measurements
The following variables were considered in the development of the risk prediction
model: age (18–24, 25–39 and ≥40 years), sex assigned at birth (male/female), race
(Black/other), transgender status (yes/no), Hispanic ethnicity (yes/no), homelessness
(includes homeless patients and patients in transient or transitional housing) (yes/no),
CDC-defined AIDS status as of 2016 (yes/no), viral suppression in 2016 (yes/no),
getting the food he/she needs (yes/no), access to transportation for
healthcare/dental/social service appointments (yes/no), alcohol/drug use resulting in any
legal problems, hazardous situations or problems in patient’s daily activities, history of
injection drug use, including injection drug use as the self-reported vector for the original
HIV infection (yes/no), self-reported feelings of depression or anxiety (yes/no), and
income <100% of the federal poverty level (FPL) (yes/no). Federal poverty level <100%
in 2016 was defined as having a household income less than $11,880 for a single person
(United States Department of Health and Human Services, 2016). Problematic
alcohol/drug use was derived from three questions namely: (a) Has alcohol/drug use
resulted in hazardous situation, (b) Has alcohol/drug use resulted in legal problems, and
(c) Is your alcohol/drug use preventing you from carrying out your daily activities?
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History of injection drug use (IDU) includes injection drug users, and men who have sex
with men who are also injection drug users.
Outcome
The outcome of the study was non-retention in HIV care in 2017. We defined
retention in care as having evidence of at least two occurrences of any combination of (a)
face-to-face encounter(s) with a Ryan White Program medical care professional, or (b)
laboratory tests (CD4 or viral load), at least three months apart during 2017.
Analysis
First, we selected risk factors to be included in the bivariate analysis based on
evidence from literature and completeness of information in the dataset, and we estimated
unadjusted odds ratios. Variables associated with non-retention in HIV care at pvalue<0.1 in bivariate analysis were included in the initial multivariate logistic regression
model. We used stepwise backward elimination, retaining variables which maintained
significance at P < 0.05 in the ﬁnal model. We used Akaike information criterion (AIC)
to check the model fit (Lee et al., 2016). We checked for any confounding effect of the
excluded variables in the final model. Discrimination was assessed using concordance
statistic or C-statistic (which is equal to the area under the receiver operating
characteristic [ROC] curve), and calibration was assessed using calibration plots by
dividing subjects into deciles of risk (Steyerberg et al., 2010).
We validated the risk score tool internally using the bootstrap method with the
original derivation data set. A total of 1000 samples were created by sampling with
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replacement, and each bootstrap sample was the same size as the original derivation
sample. For each sample, the model was refitted following the same method adopted in
the derivation process. We computed model performance (C-statistic) on each bootstrap
sample and compared it with the model performance in the original data to calculate
optimism (magnitude of bias). The optimism-adjusted C-statistic was computed by
subtracting the optimism from the original C-statistic (Steyerberg, 2009).
Finally, we generated a simple integer-based risk score for each predictor variable
by multiplying the beta coefficients by 10 and rounding to the nearest integer (Bengtson
et al., 2016; Steyerberg, 2009). The total risk score was calculated by adding each
component together. We divided the population into strata based on quartiles of the total
risk score by placing cut points at the 25th, 50th and 75th percentiles (Traeger et al., 2015;
Chan et al., 2012). We also calculated the sensitivity and specificity at each risk score
cutoff point. The predictive performance of the risk score was evaluated by means of
discrimination and calibration. All analyses were conducted using SAS software V. 9.4
(SAS Institute Cary, NC). This study was approved by the Florida International
University Institutional Review Board.
Results
Of the total 9011 PHIV enrolled in RWP in 2016, 7439 people were included in
our analysis. A total of 1572 PHIV were excluded for various reasons (Figure 1). About
24% (1759) of the 7439 were not retained in HIV care during 2017. The mean age and
standard deviation of the study population was 44.4±11.9 years. About 64% of the
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population were older than 40 years, 59.7% were Black, 76.2% were male, and 55.7%
were Hispanic (Table 1).
Of the 14 potential variables considered, 11 variables were associated with nonretention in HIV care at p-value <0.1. In the bivariate analysis, age in 2016, race, poverty
level, homelessness, alcohol/drug use resulting in any problem in daily activity, legal
issue or hazardous situation, viral suppression status, Hispanic ethnicity, feeling
depressed or anxious and food need were significant at p-value <0.001; whereas history
of IDU and access to transportation were significant at p-value <0.05 (Table 1). Sex
assigned at birth, transgender status, and AIDS status as of 2016 were not associated with
retention in care in 2017 (p-value>0.1). In the stepwise logistic regression analysis, six
variables maintained significance level at p-value <0.05 level in the final model (Table
1). The six variables were age, race, poverty level, homelessness, alcohol/drug use
resulting in any problem in daily activity, legal issue or hazardous situation, and viral
suppression status. The discrimination of the overall model with the 6 variables was
0.654 (Figure 2(a)), and after adjusting for optimism, the discrimination was 0.651.
Based on the calibration plot, the agreement between the observed and predicted
proportion of events of non-retention in HIV care showed good apparent calibration
(Figure 2(b)).
The final risk prediction tool included 6 risk factors present in 2016 that can be
used to predict non-retention in HIV care over the course of 2017 (Figure 3). Each risk
factor contributed additively to an overall risk score, as follows: having unsuppressed
viral load had a risk score of 5, being homeless had a risk score of 3, being Black had a
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risk score of 2, being in the age group 18-24 had a risk score of 1, being in the age group
25-39 had a risk score of 2, having income below 100% of the federal poverty level had a
risk score of 1, and alcohol/drug use resulting in any problem in daily activity, legal issue
or hazardous situation had a risk score of 4. The minimum total risk score was 0 for a
person without any of the risk factors, and the maximum possible risk score was 17. A
person with a total risk score of 0 had 14.4% probability of not being retained in HIV
care in 2017, and a person with a total risk score of 17 had 82.5% probability of not being
retained in HIV care. As the risk score increased, the probability of non-retention in care
increased. Every one-point increase in the risk score scale was associated with OR 1.22
(95% CI; 1.20−1.24) increase in non-retention in care. The discrimination of the risk
score was 0.650. We divided the risk scores into three categories based on quartiles
placing cut points at the 25th and 75th percentiles. There were 1559 (21.0%) people in
the first quartile (0 risk score), and 211 (13.5%) of these were not retained in HIV care. In
the second and third quartiles (score 1–4), there were 4331 (58.2%) people, and in the
upper quartile (>4 risk score) there were 1549 people (20.8%). About 20% (882) of those
in the second and third quartiles and 43.0% (666) of those in the upper quartile were not
retained in HIV care. Compared to those in the first quartile, those who were in the
middle two quartiles and those in the upper quartile were more likely not to be retained in
care (OR 1.63 [CI; 1.39−1.92] and OR 4.82 [CI; 4.04−5.78], respectively). The cutoff
value of 4 had a sensitivity of 43% and specificity of 80% and a cutoff value of 5 had a
sensitivity of 38% and specificity of 84%. Similarly, a cutoff value of 3 in the risk score
had a sensitivity of 56% and specificity of 65%.
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Discussion and Conclusion
In this study, we derived and internally validated a risk prediction tool for nonretention in HIV care in the next year using retrospective data from Miami-Dade County
RWP Part A/MAI. This risk prediction tool can be used in clinical settings by HIV care
providers to identify PHIV who will not be retained in HIV care in the next year. We
found that the risk score constitutes age group, race, poverty level, homelessness,
problematic alcohol/drug use and viral suppression status. These variables can be
extracted easily from medical records or by interviewing the patient and can be
implemented in a variety of settings.
The individual factors included in our risk prediction tool have been previously
found to predict retention in care. Consistent with findings in previous studies,
unsuppressed viral load and age group predict retention in HIV care (Giordano et al.,
2009; Nosyk et al., 2015; Lourenço et al., 2014; Tripathi et al., 2011; McNairy et al.,
2018; Woodward et al., 2015). Similarly, persons living with HIV who are homeless or
have low economic status have been found to be poorly retained in care ) (Centers for
Diseases Control and Prevention, 2018; Giordano, 2011; Rajabiun et al., 2018; Wolitski
et al., 2007). This is likely due to unmet social service needs (Wolitski et al., 2007).
People who use alcohol/drugs are at increased risk of poor adherence and non-retention
in HIV care (Vagenas et al., 2015; Edison et al., 2014; Williams et al., 2016; Gwadz et
al., 2016). This may be due to the behavioral factors associated with alcohol/drug use.
Moreover, being Black/African American has been identified as a risk factor increasing
non-retention in care. Historical and cultural factors as well as structural racism may
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affect the retention of African Americans in HIV care (Freeman et al., 2017). Therefore,
inclusion of Black race in the risk prediction tool is likely a proxy for underlying social,
cultural, and economic factors. Inclusion of race in the risk prediction tool may lead to
unconscious bias by health care providers about Blacks. Addressing racial bias needs
comprehensive, multifaceted, and evidence-based interventions at the individual and
organizational level including leadership commitment to a cultural inclusion, diversity
training, self-reflection on personal biases, mentorship and sponsorship, and cultural
competency (Marcelin et al., 2019).
We stratified the population into quartiles, and patients with a total risk score >4
were classified in the fourth quartile. The risk of non-retention in care showed a graded
increase across the quartiles. Those who were in the fourth quartile were about 5 times
more likely not to be retained in care than those who were in the first quartile. A cutoff
value of 5 in the risk score had a sensitivity of 38% and a specificity of 84%. This cutoff
identified 20.8% of our study population with the highest likelihood of non-retention in
care for intervention. Based on this risk score cutoff, non-viral suppression, independent
of other factors in the risk score, contributes to one third of the total risk score. Thus,
viral suppression is a good predictor to use for identifying patients that may benefit from
a retention intervention. Alternatively, a lower cutoff point in the risk score would yield
higher sensitivity and lead to targeting a larger proportion of the population for a
retention intervention.
Previous risk prediction tools developed to predict patient adherence to
appointments or retention in care were either restricted to specific populations or had
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different outcome definitions. The study by McNairy et al. measured lost to follow-up
based on a single clinic or pharmacy visit during 365 days after ART initiation (McNairy
et al., 2018). Our definition of retention in care was based on two or more clinic visits or
laboratory tests at least three months apart during a year. Bengtson et al. developed a risk
prediction tool among HIV-infected women, and they included different predictors
specific to pregnant women such as parity and number of antenatal care visits (Bengtson
et al., 2016). Woodward et al. used a tool previously developed for virologic failure to
stratify patients based on medical appointment attendance (defined based on a single
visit) among persons with unsuppressed viremia (Woodward et al., 2015). The definition
of the outcome and the target population are different from ours. Some factors such as
substance use and viral suppression were common predictors in our risk prediction tool
and theirs. However, Woodward et al included additional predictors such as prior
treatment failure, adherence to daily medications, history of missing HIV care
appointments, and prior exposure to ART which may be better predictors of retention in
care but are not readily collected in our study.
The risk prediction tool is intended to be used in HIV care settings, where the
characteristics of the target population are similar to ours. Upon arrival of a patient to the
HIV care setting, an HIV care provider could assess the probability of a patient not being
retained in HIV care in the next year using this checklist. Depending on the availability of
resources, HIV care providers may arrange for an intervention to support retention based
on severity of risk in order to improve HIV outcomes (Samji et al., 2013; Montaner,
2011) and reduce HIV transmission (Cohen et al., 2011; Shah et al., 2015). Retention in
HIV care can be improved by incorporating informational, motivational, and behavioral
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skill components (Giordano, 2011). Peer navigators and clinic-wide marketing (e.g.,
posters, brochures) including targeted messages on staying in care which were delivered
at minimal effort and cost, have been found to be effective in improving clinic attendance
(Centers for Diseases Control and Prevention, 2018; Gardner et al., 2012; Gardner et al.,
2015). Designating a staff person to help with appointments, referrals, system navigation,
service coordination, and transportation may improve retention in HIV care (Centers for
Diseases Control and Prevention, 2018; Okeke et al., 2014). Enhancing personal contact
with patients and asking open-ended questions in regular conversations at every office
visit may help to identify specific ART adherence and retention support services (Centers
for Diseases Control and Prevention, 2018; Gardner et al., 2014).
Our study has several limitations. First, in our analysis, we included variables that
are routinely collected and easily available to care providers. However, these variables
were not strong predictors of non-retention in care. The discriminative ability of our
study is low (0.651) (Lloyd-Jones et al., 2010), although it is higher than that of the study
by McNairy et al (McNairy et al., 2018). Moreover, we were not able to find a risk score
cutoff with higher sensitivity and specificity. This indicates that other predictive variables
could have been included in the risk prediction tool to improve its discriminative ability.
Factors such as adherence to daily medications, sexually transmitted infections, previous
appointment attendance, prior treatment failure (Woodward et al., 2015), and other unmet
needs (Centers for Diseases Control and Prevention, 2018; Giordano, 2011) may increase
the discriminative ability of the risk prediction tool. However, information about these
factors may not be routinely accessible to the HIV care providers, or collecting these
factors may require additional resources and increase the workload for HIV care
23

providers or support staff. Although the discrimination level is relatively low, this tool
can be used in situations where these additional variables are not available. Second, we
used RWP Part A/MAI data to develop and internally validate our risk prediction tool.
The Ryan White Program provides medical care, medical case management, antiretroviral prescription drugs and other support for PHIV without health insurance. Thus,
Ryan White Program participants may not be representative of all PHIV. Third, people
newly diagnosed with HIV may behave differently due to experiencing additional
challenges related to acceptance of their diagnosis and stigma. Therefore, they may
require a different risk prediction tool. Finally, of those enrolled in 2016, we were not
able to find laboratory results for 917 people during 2017. In a separate analysis, we
excluded those people, and the results were similar with the model that included those
917 people.
In summary, we developed a relatively simple prediction tool that can be used to
identify PHIV who are at risk of non-retention in HIV care. This tool includes
characteristics that are routinely collected in healthcare settings. These factors include
age group, race, poverty level, homelessness, problematic alcohol/drug use and viral
suppression status. The risk prediction tool has low discrimination power but could be a
good alternative tool in situations where additional data is not available. Further research
should include better predictive variables to enhance the accuracy of this risk prediction
tool.
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Tables and figures
Table 1. Population characteristics and model of risk variables associated with non-retention in care among PHIV (N=7439)
Characteristics during
Total
Not retained in
Bivariate analysis
Multivariate analysis
2016
population
care n (%)
Unadjusted OR
p-value
Adjusted OR
Coefficient
(n)
(95% CI)
(95% CI)
(Beta)
Total
7439
1759 (23.7)
Age (years)
<0.001
18–24
413
142 (34.4)
0.05
1.85 (1.57−2.42)
1.51 (1.21−1.90)
25–39
2256
608 (30.0)
0.21
1.38 (1.22−1.54)
1.31 (1.16−1.48)
≥40
4770
1009 (21.2)
Ref
Ref
Race
<0.001
Other
4443
889 (20.0)
Ref
Ref
Black
2996
870 (29.0)
0.16
1.64 (1.47−1.82)
1.37 (1.22−1.53)
Income below 100% of
<0.001
FPL
No
4178
840 (20.1)
Ref
Ref
Yes
3261
919 (28.2)
0.11
1.56 (1.40−1.74)
1.24 (1.11−1.40)
Homeless
<0.001
No
6983
1567 (22.4)
Ref
Ref
Yes
456
192 (42.1)
0.27
2.51 (2.07−3.05)
1.80 (1.46−2.23)
Alcohol/drug use
<0.001
resulted in any problem
in daily activity, legal
issue or hazardous
situation
Yes
192
106 (55.2)
0.43
4.17 (3.12−5.57)
2.36 (1.72−3.23)
No
7247
1653 (22.8)
Ref
Ref
Virally suppressed
<0.001
Yes
6232
1224 (19.6)
Ref
Ref
No
1207
535 (44.3)
0.49
3.26 (2.86−3.71)
2.69 (2.35−3.07)
Sex assigned at birth
0.56
29

Score

1
2

2

1

3

4

5

Male
5667
1349 (23.8)
Ref
Female
1772
410 (23.1)
1.04 (0.92−1.18)
Hispanic ethnicity
<0.001
Yes
4143
813 (19.6)
Ref
No
3296
846 (25.7)
1.41 (1.28−1.58)
Are you feeling
<0.001
depressed or anxious?
Yes
1146
305 (30.5)
1.52 (1.33−1.75)
No
6293
1409 (22.4)
Ref
Are you getting the food
<0.001
you need?
Yes
7322
1717 (23.5)
Ref
No
117
42 (35.9)
1.83 (1.25−2.68)
CDC-defined AIDS
0.13
Yes
3041
746 (24.5)
1.09 (0.98−1.21)
No
4398
1013 (23.0)
Ref
History of IDU
0.030
No
7309
1714 (23.5)
Ref
Yes
130
45 (34.6)
1.73 (1.20−2.49)
Access to transportation
0.01
to appointments
Yes
6726
1563 (23.2)
Ref
No
713
196 (27.5)
1.25 (1.05−1.49)
Transgender
0.44
No
7396
1751 (23.7)
Ref
Yes
43
8 (18.6)
0.74 (0.34−1.59)
OR: Odds Ratio; FPL: Federal Poverty Level; IDU: Injection Drug Use; AIDS: Acquired Immunodeficiency Syndrome; CI: Confidence
Interval; CDC: Centers for Diseases Control and Prevention
The multivariate logistic model included variables that were significant at p-value <0.1 in the bivariate analysis. These include all the variables
in the table except sex assigned at birth, AIDS status and transgender status.
Scores were assigned to each risk factor by multiplying each beta obtained from the stepwise logistic regression model by 10.
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Figure 1. Diagram for exclusion of participants from the present study
9011
Total PHIV enrolled in 2016 calendar year
(at least one medical case management encounter or peer education
support network service)

150 excluded (case closed because of
financial ineligibility or movement to
other locations or incarceration for greater
than 6 months)

25 excluded (under 18 years old)

23 excluded (died in 2016 or
2017)
55 excluded (newly diagnosed or
received their first instance of Ryan
White care in 2016 and had no viral load
measurement in 2016)

993 excluded (had no
comprehensive health assessment
in 2016)

4 excluded (had missing
information on problematic
alcohol/drug use)

322 excluded (out-of-network referrals)

7439
Final study population
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Figure 2. a) Discrimination of the final model b) Calibration of the final model
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Figure 3. Point scores for all risk factors in the logistic regression model
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MANUSCRIPT 2
Gebrezgi M.T., Fennie K.P., Sheehan D.M., … & Trepka MJ. (2020). Development and
validation of a risk prediction tool to identify people living with HIV likely not to achieve
viral suppression. AIDS Pt Care and STDs. In press.
Abstract
Introduction: Identifying people with HIV (PHIV) who are at risk of not achieving viral
suppression is important for targeted intervention. The aim of this study was to develop
and test a risk prediction tool for PHIV who are at risk of not achieving viral suppression
after a year of being in care.
Methods: We used retrospective data to develop an integer-based scoring method using
backward stepwise logistic regression. We also developed risk score categories based on
the quartiles of the total risk score. The risk prediction tool was internally validated by
bootstrapping.
Results: We found that non-viral suppression after a year of being in care among PHIV
can be predicted using seven variables, namely; age group, race, federal poverty level,
current AIDS status, current homelessness status, problematic alcohol/drug use and
current viral suppression status. Those in the high-risk category had about 23 increase in
the odds of non-viral suppression compared to the low-risk group. The risk prediction
tool has good discriminative performance and calibration.
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Conclusions: Our findings suggest that non-viral suppression after a year of being in care
can be predicted using routinely available variables. In settings with similar
demographics, the risk prediction tool can assist healthcare providers in identifying highrisk individuals to target for intervention. Follow-up studies are required to externally
validate this risk prediction tool.
Keywords: HIV, AIDS, viral suppression, risk prediction tool, risk score
Introduction
In the United States, at the end of 2015, about 1.1 million people were living with
HIV, and in 2015, there were an estimated 38,000 new HIV infections (Centers for
Diseases Control and Prevention, 2018). In 2017, Florida had the highest number of
estimated new HIV infections (4800) (Centers for Diseases Control and Prevention,
2018(a)). Within Florida, Miami-Dade County had the highest number of people with
HIV (PHIV); approximately 29,969 in 2017 (Florida Department of Health, 2018).
Once diagnosed with HIV, PHIV need to be linked to and retained in care, take
antiretroviral therapy (ART) and adhere to their medications in order to have successful
HIV care outcomes. The HIV care continuum, defined as stages of HIV medical care that
PHIV go through, from initial diagnosis to achieving viral suppression (U.S. Department
of Health & Human Services, 2016), includes five steps, namely HIV diagnosis, linkage
to HIV care, retention in HIV care, adherence to ART, and viral suppression (Kay et al.,
2016). Viral suppression is the final step and ultimate goal of the HIV care continuum
and is usually a reflection of success in HIV care. Viral suppression benefits the
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individual living with HIV and the community. Virally suppressed PHIV have slower
disease progression and increased survival (Lima et al., 2007; Montaner, 2011; Samji et
al., 2013). At the community level, virally suppressed individuals are less likely to
transmit the virus to others (Philbin et al., 2014; Cohen et al., 2011; Shah et al., 2015).
Despite the availability of ART, a substantial number of PHIV are not virally suppressed
(Centers for Diseases Control and Prevention, 2017). For example, in 2015, in 39 US
states and District of Colombia, 40.2% of the PHIV were not virally suppressed (Centers
for Diseases Control and Prevention, 2018(b)).
Given the importance of viral suppression, there is a need to develop evidencebased strategies to monitor and predict this outcome. There are numerous cross-sectional
and longitudinal studies which have identified factors associated with viral suppression
among PHIV (Crepaz et al., 2018; Whiteside et al., 2014; Sheehan et al., 2017; Joseph
Davey et al., 2018; Geter et al., 2018; Castel et al., 2016; Colasanti et al., 2015;
Muthulingam et al., 2013; Tanner et al., 2016; Blank et al., 2015; Myers et al., 2016; Beer
et al., 2016). These factors include young age (Crepaz et al., 2018; Whiteside et al.,
2014), gender (Whiteside et al., 2014; Sheehan et al., 2017; Joseph Davey et al., 2018),
Black race (Crepaz et al., 2018; Sheehan et al., 2017; Geter et al., 2018; Castel et al.,
2016; Colasanti et al., 2015), unstable housing (Muthulingam et al., 2013), substance use,
higher baseline viral load (Tanner et al., 2016), long duration of HIV infection (Castel et
al., 2016), poor general health status (Castel et al., 2016; Blank et al., 2015), being US
born (Myers et al., 2016), and low educational attainment (Beer et al., 2016). There is a
need to translate these findings about individual factors into validated and easy-to-use
risk tools for use in predicting an individual’s risk of not achieving viral suppression.
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Studies have been conducted to develop risk prediction tools for virologic failure
(Robbins et al., 2010), and for predicting extended high viremia among newly diagnosed
people (Powers et al., 2018). Clinical and behavioral factors related to sub-optimal
adherence, recent CD4 count, drug and/or alcohol abuse, prior ART exposure, prior
treatment failure, and recent HIV-1 viral load were used to predict virologic failure after
one year among those who were virologically suppressed on ART at enrollment (Robbins
et al., 2010). Researchers have also developed risk prediction tools for HIV disease
progression, particularly for mortality (Mocroft et al., 2007; Bebu et al., 2014; Nugent et
al., 2014). The aim of our study was to develop and test a risk prediction tool for PHIV
who are in care but are at risk of not achieving viral suppression after a year of being in
care, to use for triaging those in need of more assistance. If people likely not to achieve
viral suppression are identified early, intervention strategies could be implemented to
assist these individuals into achieving viral suppression and ultimately improve their
quality of life (National Institute of Health, 2015).
Methods
Data source and study population
We developed and internally validated a risk prediction tool for non-viral
suppression using retrospective data from the Miami-Dade County Ryan White Program
(RWP) Part A/ Minority AIDS Initiative (MAI) for the calendar years 2016–2017. The
dataset included 6492 PLWH who were in care in 2016 and 2017 in the RWP Part
A/MAI. In care was defined as having at least one viral load or cluster of differentiation 4
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(CD4) count test in each year. All exposures were measured in 2016, and viral
suppression was measured in 2017.
The Ryan White Program is a comprehensive system of care for PHIV. It
provides primary medical care and other support for PHIV without health insurance. In
the US, more than half of PHIV receive services through the Ryan White HIV/AIDS
Program each year (Ryan White HIV/AIDS Program, 2019). The Ryan White Program
services include outpatient/ambulatory health services, oral health care, other
professional services (legal services and permanency planning), food bank, medical
transportation (in the form of vouchers), mental health services, medical case
management (including treatment adherence), health insurance premium and cost sharing
assistance, local AIDS pharmaceutical assistance, substance abuse care and services (both
outpatient and residential), and outreach services.
Predictor variables
We selected sociodemographic, clinical and behavioral variables based on
evidence from the literature and completeness of information in the dataset (Crepaz et al.,
2018; Whiteside et al., 2014; Sheehan et al., 2017; Joseph Davey et al., 2018; Geter et al.,
2018; Castel et al., 2016; Colasanti et al., 2015; Muthulingam et al., 2013; Tanner et al.,
2016; Blank et al., 2015; Myers et al., 2016; Beer et al., 2016). All characteristics were
parameterized as categorical variables and refer to the year 2016. Age was categorized as
18–24, 25–39, and ≥40 years. All other variables were binary and included sex assigned
at birth (male/female), homelessness (yes/no), race (Black/ White or other), transgender
(yes/no), Hispanic ethnicity (yes/no), alcohol/drug use resulting in any problem in
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patients daily activity or legal issue or hazardous situation (referred as problematic
alcohol/drug use in this manuscript) (yes/no), self-reported feelings of depression or
anxiety (yes/no), patient getting the food he/she needs (yes/no), patient had CDC-defined
AIDS as of 2016 (yes/no), patient virally suppressed in 2016 based on the last viral load
laboratory test in 2016 (yes/no), patient had access to transportation for
healthcare/dental/social service appointments (yes/no), patient had a history of injection
drug use (yes/no), and federal poverty level (FPL) <100% (yes/no). Federal poverty level
<100% in 2016 was defined as having a household income less than $11,880 for a single
person (United States Department of Health and Human Services, 2016). We defined
problematic alcohol/drug use as having any of the following; (a) Has alcohol/drug use
resulted in legal problems? (b) Has alcohol/ drug use resulted in hazardous situation? and
(c) Is your alcohol/drug use preventing you from carrying out your daily activities? All
predictor variables were obtained from the patient intake assessment (information
collected at time of entry into the RWP Part A/MAI, comprehensive health assessment
(bi-annual assessment of all RWP Part A/MAI patients) or laboratory data.
Outcome
The outcome, viral suppression, was a binary variable, and non-viral suppression
was defined as having viral load ≥200 copies/mL in the last viral load measurement in
2017 (Centers for Diseases Control and Prevention, (2018(c)).
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Inclusion and exclusion criteria
We included PHIV who were in care in 2016 and 2017 and who had a
comprehensive health assessment in 2016. Comprehensive health assessment is a health
and social needs assessment of a Ryan White Program patients that is completed every 6
months to determine plan of care and need for referrals to other services. Patients who
were less than 18 years old in January 2016, died in 2016 or 2017, had no comprehensive
health assessment in 2016, or were out-of-network referrals in 2016 or 2017were
excluded. Out-of-network referrals are people who were referred to the RWP from a nonRWP provider. Patients whose case was closed because of moving to another
state/county, financial ineligibility, or incarceration for greater than six months during
2016 or 2017 were also excluded.
Analysis
First, we conducted bivariate analysis to assess the association between each
predictor variable and the outcome and estimated crude odds ratio (OR). All variables
associated with non-viral suppression at p<0.1 in the bivariate analysis were included in
the initial logistic regression model. With stepwise backward elimination, we retained
only signiﬁcant factors (P < 0.05) in the ﬁnal model (Steyerberg, 2009).
We assessed calibration using calibration plots by dividing subjects into deciles of
risk according to their model predictions, and the observed non-viral suppression levels
among the subjects. Each decile was plotted against the average predicted probability of
non-viral suppression and compared to the 45° line (perfect calibration) (Steyerberg et al.,
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2010). The ability of the prediction model to distinguish events versus non-events
(discrimination) was measured by the concordance statistic or C-statistic (which is equal
to the area under the receiver operating characteristic (ROC) curve) (Steyerberg et al.,
2010).
We assessed internal validity with a bootstrapping procedure, extracting 1,000
samples with replacement, of the same size as the original data set (n = 6,492)
(Steyerberg et al., 2001; Han et al., 2016). For each sample, we used the same procedure
that was used in the original dataset (stepwise backward logistic regression model). Then
we calculated optimism by comparing the final model performance (C-statistic) of
bootstrap samples with that of the original data. The bootstrap- corrected C-statistic was
computed by subtracting the optimism from the original C-statistic (Steyerberg, 2009).
Risk score development
We aimed to develop a simple risk score tool that could be easily assessed in a
variety of settings to identify PHIV who are at risk of not achieving viral suppression
after a year of being in care. After obtaining the beta coefficients from the final logistic
regression model, the scores for each predictor were determined by multiplying each beta
coefficient by 10 and rounding to the nearest integer (Steyerberg, 2009; Austin et al,.
2016).
The total risk score was calculated by adding the scores for all existing risk
factors. In order to develop an easily interpretable method to classify patients according
to the risk of not achieving viral suppression, we divided the risk score into three strata
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(by placing cut points at the 25th and 75th percentiles of the model's total risk score
distribution). We also calculated sensitivity, speciﬁcity, positive predictive value, and
negative predictive value for a range of potential cutoff points. All statistical analyses
were performed using SAS software version. 9.4 (SAS Institute Cary, NC). This study
was approved by the Florida International University Institutional Review Board.
Results
Of the 8014 PHIV who were in care in the RWP Part A/MAI in 2016 in MiamiDade County, 1522 (19.0%) excluded for various reasons (Figure 1); 571 of whom were
not in care in 2017. Of the 6492 PHIV in the final dataset, 606 (9.4%) were not virally
suppressed in 2017.
The majority of the PHIV were >40 years old (65.8%), male (76.3%), and virally
suppressed in 2016 (87.5%) (Table 1). In the bivariate analysis, age in 2016, race,
Hispanic ethnicity, poverty level, homelessness, problematic alcohol/drug use, feeling
depressed or anxious, viral suppression status in 2016, and AIDS status as of 2016 were
associated with non-viral suppression in 2017 at p<0.001; whereas food needs, history of
injection drug use (IDU), and sex assigned at birth were associated with non-viral
suppression in 2017 at p<0.05. Transgender status and access to transportation to
appointments were not associated with non-viral suppression in 2017.
In the stepwise backward logistic regression model, 12 variables were entered in
the initial model, and seven variables maintained statistical significance at p-value <0.05.
These risk factors include being in the age group 25-39 (β=0.27, p<0.001)) or age group
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18-24 (β=0.06, p<0.05), Black race β=0.32, p<0.001), poverty level <100% (β=0.17,
p<0.001), homelessness (β=0.27, p<0.001), problematic alcohol/drug use (β=0.37,
p<0.001), diagnosed with AIDS as of 2016 (β=0.24, p<0.001), and not virally suppressed
in 2016 (β=0.91, p<0.001) (Table 2). The C-statistic for the derivation model was 0.767%
(Figure 2). The optimism-corrected C-statistic was 0.763% (optimism=0.004). The
calibration plot shows good calibration with a predicted and observed probability of viral
suppression aligning with the 45° line.
The risk score ranged from 0 to 26 (Figure 4). A patient will have highest risk
score (score=26) if the patient is aged 25-39, Black, homeless, poverty level<100%, had
AIDS as of 2016, had problematic alcohol/drug use and had unsuppressed viral load in
2016. Non-viral suppression in 2016 greatly predicted non-viral suppression in 2017, and
more than one-third of the total risk score was contributed by this variable. The
simplified integer-based risk score performed well in the derivation dataset (Cstatistic=0.768%). The distribution of predicted and observed percentage by these risk
scores is provided in figure 3 (Figure 3). An increase of one point in the risk score was
associated with 1.2 increase in the odds of non-viral suppression (OR 1.22; 95 CI, 1.201.24).
Figure 4 shows a one-page scoring and decision tool that can be used in health
facilities. This scoring and decision tool includes the list of the seven variables and space
to record the score for each variable and a total score. On the right side, it includes the
risk of non-viral suppression associated with each total score computed from the risk
prediction score. To illustrate the application of the risk score, consider a patient who is
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27-year-old, Black, has a household poverty level >100%, has permanent housing, has no
problematic alcohol/drug use, presents with AIDS diagnosis and has an unsuppressed
viral load. Then according to figure 4, the total risk score of the patient can be calculated
as 3+3+0+0+0+3+9 which will add up to 18. Looking at the right side of figure 4, this
person has a 49.0% probability of not being virally suppressed by the end of next year.
Based on the percentile distribution of the total risk score, we created three
categories. These were low risk (score 0–1), medium risk (score 2–7) and high risk (score
≥8). About 15% (n=969) of the study population were in the low risk category, and 1.6%
(n=15) of these were not virally suppressed. About 65% (n=4243) of the study population
were in medium risk category, of whom 6.0% (n=255) were not virally suppressed.
About 20% (n=1280) of the study population were in the high-risk category, and 26.5%
(n=339) of these were not virally suppressed. Compared to those who were in the lowrisk category, those who were in medium risk and high risk category were more likely
not to be virally suppressed (OR 4.06 [CI; 2.40–6.87] and OR 22.89 [CI; 13.54–38.68],
respectively).
We estimated sensitivity, specificity and predictive values for various cutoff
points in the risk scoring tool. Use of ≥7 as a risk score cutoff point has a sensitivity of
63%, specificity of 77%, positive predictive value of 21% and negative predictive value
of 95%; whereas use of ≥8 as a cutoff point has a sensitivity of 57%, specificity of 85%,
positive predictive value of 31%, and negative predictive value of 94%. Use of ≥9 as a
cutoff point has a sensitivity of 52%, specificity of 88%, positive predictive value of
31%, and negative predictive value of 94%.
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Discussion and Conclusion
We found that non-viral suppression by the end of one-year follow-up time can be
predicted using seven variables which are easily ascertained by patient history and
medical record. These variables include current age group, race, poverty level, current
AIDS diagnosis, current homelessness, problematic alcohol/drug use, and current viral
suppression status. The risk prediction tool has a total risk score of 26, and the risk for
non-viral suppression increases as the risk score increases. In addition to predicting the
magnitude of risk of non-viral suppression associated with each risk score, we also
stratified the cohort into risk groups. Those in the high-risk category had about 23 times
the risk of having non-viral suppression compared to the low-risk group. The risk
prediction tool has good discriminative performance and calibration.
Many studies have identified individual risk factors associated with poor
attainment of viral suppression (Crepaz et al., 2018; Whiteside et al., 2014; Sheehan et
al., 2017; Joseph Davey et al., 2018; Geter et al., 2018; Castel et al., 2016; Colasanti et
al., 2015; Muthulingam et al., 2013; Tanner et al., 2016; Blank et al., 2015; Myers et al.,
2016; Beer et al., 2016). Previous studies have shown the predictive role of age group,
race, poverty level, AIDS diagnosis, alcohol/drug use, and homelessness on viral
suppression (Crepaz et al., 2018; Whiteside et al., 2014; Sheehan et al., 2017; Geter et al.,
2018; Castel et al., 2016; Colasanti et al., 2015; Muthulingam et al., 2013; Tanner et al.,
2016; Robbins et al., 2010; Powers et al., 2018; Mocroft et al., 2007). Poverty and
homelessness may be predictive of viral suppression due to competing needs (Kalichman
et al., 2015). AIDS status could affect viral suppression due to advanced nature of the
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disease (Langebeek et al., 2014). The predictive role of current viral load to future
virologic failure and other HIV disease progression has been demonstrated in previous
risk prediction tools (Robbins et al., 2010; Mocroft et al., 2007). There is no evidence of
direct mechanism through which race can predict viral suppression. In populations
without great disparities in socioeconomic status and access to care such as the military
(Silverberg et al., 2009) and populations who receive care from culturally competent
healthcare providers (Saha et al., 2013), Black race has not been found to be predictive of
HIV care outcomes. In the current study, Black race is likely serving as a proxy for
unmeasured factors such as low educational level, stigma, discrimination, mistrust of the
health system, and quality of provider relationship that may be differentially affecting the
Black PHIV (Centers for Diseases Control and Prevention, 2019; Freeman et l., 2017;
Gaston et al., 2013).
Healthcare providers can use different cutoff points depending on availability of
resources. If we consider sensitivity and specificity equally important, the cutoff value of
7 in the risk score gave a maximized value of sensitivity and specificity (63% and 77%
respectively). The corresponding positive and negative predictive values were 21% and
95%, respectively. However, based on the importance of false-positives and falsenegatives, healthcare providers may choose to use different cutoff points. The cutoff
point 7 identiﬁed 62% of individuals who failed to achieve viral suppression in next year
whereas the cutoff point 9 identiﬁed 52% of individuals who failed to achieve viral
suppression in next year. Moreover, the cutoff point 7 would put 26.8% of our population
for intervention whereas the cutoff point 9 would put 15.7% of our population for
intervention. A lower cutoff value in the risk score would put a large proportion of our
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population into a group to be targeted for intervention and would identify the majority of
individuals who failed to achieve viral suppression in next year.
Our study builds on Robbins et al study using more recent data. But our study is
different from the Robbins et al study in the definition of the outcome. Robbins et al
included patients who were virologically suppressed on ART at enrollment and defined
virologic failure as 1) two consecutive measurements of HIV RNA level of >400
copies/mL or 2) one measurement of HIV RNA level of >400 copies/mL and no
confirmatory test in the subsequent 3 months (Robbins et al., 2010). In our study, we
included all PHIV regardless of viral suppression status, and our outcome of interest,
non-viral suppression was defined as having viral load ≥200 copies/mL in the last viral
load measurement of the subsequent year. Moreover, while Robbins et al included factors
such as adherence to ART and prior antiretroviral history, which are not available in our
dataset, our study considered additional socioeconomic factors such as poverty level,
access to transportation to medical appointments, food needs, transgender status and
AIDS status to develop the risk prediction model.
We attempted to explore alternative models with a reduced number of predictors
(data not shown). After we exclude homelessness from the model, the discriminative
performance of the model was similar (C-statistic=0.763). In order to assess the
performance of the model in situations where viral load measurement is not available, we
excluded viral suppression status in 2016 from the model, but the C-statistic greatly
reduced to 0.70.
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Risk prediction tools that are simple to use, accurate in predicting risk, and are
generalizable across contexts, and use routinely collected variables are needed to identify
patients at high risk for poor outcomes and to provide individualized risk assessment
(McNairy et al., 2017). The risk prediction tool developed in this study needs external
validation to evaluate its performance in other populations. The risk score could be useful
in settings similar to the Ryan White Program. When a person with HIV visits an HIV
care provider, the provider can quickly and easily use this tool to predict the probability
of the person being not virally suppressed by the end of next year. Thus, the scoring can
be useful to stratify PHIV into risk categories so that resources are directed to those at
greater risk. Accordingly, patients can be targeted for intervention. Depending on the
available resources and infrastructure, multi-faceted interventions can be implemented to
improve the success of the HIV care continuum. Addressing service-related, medical and
psychosocial factors, designing community-based interventions including management
and/or patient navigation (Raj et al., 2018), home-based health care, economic
empowerment and population specific interventions such as youth friendly clinics and
services (Casale et al., 2019; Bulsara et al., 2019) could improve the success of patients
in the HIV care continuum.
About 8% (571) of those receiving care in 2016 were not in care in 2017 (lost to
follow-up). We compared the baseline characteristics of our study population (those in
care in 2017) and those lost to follow-up in 2017. Compared to our study population,
those lost to follow-up were more likely to be 25−39 years-old (36.1% vs 29.3%;
p<0.001), Black (53.9% vs 38.5%; p<0.001), non-Hispanic (59.2% vs 42.3%; p<0.001),
have a household poverty level of<100% (58.1% vs 42.0%; p<0.001), homeless (13.3%
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vs 5.2%; p<0.001), not virally suppressed in 2016 (27.3% vs 12.5%; p<0.001), feel
depressed or anxious (19.1% vs 14.8%; p<0.001), and have problematic alcohol/drug use
(7.0% vs 2.0%; p<0.001). These differences in baseline characteristics indicate that, those
lost to follow-up could have worse viral suppression status compared to our study
population.
Despite the strengths of this simple risk prediction score model, there are several
limitations that need to be acknowledged. First, we had a large sample size, and the
model had good discrimination and calibration in the bootstrapped samples, but the
model should undergo external validation to see the performance of the risk prediction
model/score in other populations. Our population included mostly low income PHIV and
had a high proportion of immigrants especially Latinos; hence the predictive performance
of the model/score may differ in a population with different sociodemographic and
behavioral characteristics from ours. Second, our study included people with new and
existing HIV diagnosis. People with new HIV diagnosis may have different challenges to
achieve viral suppression. Therefore, they may need a different risk score. Third, we
depended on self-report for feeling depressed or anxious and problematic alcohol/drug
use; this may have led to underreporting. Fourth, exposures are measured at any time
point in 2016; therefore, there might be differential follow-up time. However, we took the
first comprehensive health assessment measurement of 2016 to ensure adequate followup time. Last, we were not able to measure adherence to ART and the duration of time
the patients had been on ART. Including information about adherence to and duration of
patients under ART could have improved the discrimination of the predictive model.
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In summary, we have identified a set of readily available variables that can be
used to predict non-viral suppression after a year of being in care among PHIV. The
predictors of non-viral suppression were age group, race, poverty level, AIDS diagnosis,
homelessness, problematic alcohol/drug use, and viral suppression status. The tool has
good discriminative ability. Additionally, the tool can be used to stratify PHIV into risk
groups that can be identified for targeted intervention. In settings with similar
demographics, the risk prediction tool can assist clinicians and healthcare providers to
identify high-risk individuals and target for interventions. Follow-up studies are required
to externally validate this risk prediction tool.
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Tables and figures
Table 1. Population characteristics of PHIV (N=6492) by viral suppression status and association of factors with non-viral suppression
Characteristics
Total
Virally suppressed
Not virally
Unadjusted OR
p-value
n (%)
suppressed
(95% CI)
n (%)
Total
6492
5883 (90.6)
609 (9.4)
Age (years) in 2016
<0.001
18–24
330
287 (87.0)
43 (13.0)
1.75 (1.25–2.46)
25–39
1905
1674 (87.9)
231 (12.1)
1.61 (1.35–1.93)
≥40
4257
3922 (92.1)
335 (7.9)
Ref
Sex at birth
0.003
Male
4952
4516 (91.2)
436 (8.8)
Ref
Female
1540
1367 (88.8)
173 (11.2)
1.31 (1.09–1.58)
Race
<0.001
White/Other
3991
3742 (93.8)
249 (6.2)
Ref
Black
2501
2141 (85.6)
360 (14.4)
2.53 (2.13–3.00)
Hispanic ethnicity
<0.001
Yes
3747
3506 (93.6)
241 (6.4)
Ref
No
2745
2377 (86.6)
368 (13.4)
2.25 (1.90–2.67)
FPL <100%
<0.001
Yes
2729
2378 (87.1)
351 (12.9)
2.01 (1.69–2.37)
No
3763
3505 (93.1)
258 (6.9)
Ref
Homeless
<0.001
Yes
339
265 (78.2)
74 (21.8)
2.93 (2.23–3.85)
No
6153
5618 (91.3)
535 (8.7)
Ref
Alcohol/drug use resulted in any
<0.001
problem in daily activity or legal
issue or hazardous situation
Yes
130
89 (68.5)
41 (31.5)
4.70 (3.21–6.87)
No
6362
5794 (91.1)
568 (8.9)
Ref
Are you feeling depressed or
<0.001
anxious?
55

Yes
958
826 (86.2)
132 (13.8)
1.69 (1.38–2.08)
No
5534
5057 (91.4)
477 (8.6)
Ref
Getting the food he/she needs
<0.019
Yes
6398
5805 (90.7)
593 (9.3)
Ref
No
94
78 (83.0)
16 (17.0)
2.01 (1.17–3.46)
Had CDC-defined AIDS in 2016
<0.001
Yes
2634
2313 (87.8)
321 (12.2)
1.72 (1.46–2.03)
No
3858
3570 (92.5)
288 (7.5)
Ref
Virally suppressed in 2016?
<0.001
Yes
5682
5344 (94.0)
338 (6.0)
Ref
No
810
539 (66.5)
271 (33.5)
7.95 (6.62–9.54)
History of IDU
0.022
Yes
108
91 (84.3)
17 (15.7)
1.83 (1.08–3.09)
No
6384
5792 (90.7)
592 (9.3)
Ref
Has access to transportation to
0.137
appointments
Yes
5883
5342 (90.8)
541 (9.2)
Ref
No
609
541 (88.8)
68 (11.2)
1.24 (0.95–1.62)
Transgender
0.385
Yes
37
32 (86.5)
5 (13.5)
1.52 (0.59–3.90)
No
6455
5851 (90.6)
604 (9.4)
Ref
PHIV: People with HIV; IDU: Injection drug use; FPL: Federal Poverty Level; AIDS: Acquired Immunodeficiency Syndrome; OR: Odds ratio;
CI: Confidence Interval; CDC: Centers for Diseases Control and Prevention
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Table 2. Final predictors of non-viral suppression and associated risk scoring system
Characteristics
Beta estimate
Score*
Age in 2016
18-24
0.06
1
25-39
0.27
3
≥40
Ref
0
Race
White/Other
Ref
0
Black
0.32
3
FPL <100%
Yes
0.17
2
No
Ref
0
Homeless
Yes
0.27
3
No
Ref
0
Alcohol/drug use resulted in
any problem in daily
activity or legal issue or
hazardous situation
Yes
0.37
4
No
Ref
0
Had CDC-defined AIDS in
2016
Yes
0.24
3
No
Ref
0
Virally suppressed in 2016
Yes
Ref
0
No
0.91
9
FPL: Federal Poverty Level; AIDS: Acquired Immunodeficiency Syndrome; CDC:
Centers for Diseases Control and Prevention
*Scores are formed by multiplying the beta coefficients by 10 and then rounding to the
nearest integer
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Figure 1. Flow diagram of exclusion criteria in the present study

Reasons for exclusion

8014 – Initial population

Out-of-network referrals in 2016 or
2017 (n=177)
7837
Age <18 years old in 2016 (n=19)
7818
Case closed because of financial
ineligibility or movement to other
locations or incarceration for greater
than 6 months, or inactivity in 2016 or
2017 (n=328)
7490
Death of patient in 2016 or 2017 (n=19)

7471
Had no comprehensive health
assessment in 2016 (n=404)
7067
Not in care in 2017 (n=571)

6496
Missing in any covariate (n=4)

6492 – Final study population
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Figure 2. Receiver operating characteristic (ROC) curves for the final logistic regression model
Area under the curve=0.7674
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Figure 3. Distribution of predicted and observed percentages by these risk scores
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Figure 4. Risk score tool for non-viral suppression after a year of being in care and
predicted risks associated with total scores

61

MANUSCRIPT 3
Gebrezgi M.T., Fennie K.P., Sheehan D.M., … & Trepka MJ . Predictors of chlamydia or
gonorrhea among people with HIV in Miami-Dade County in 2017. Submitted to Journal
of Sexually Transmitted Diseases.
Abstract
Background: The aim of this study was to assess prevalence of chlamydia or gonorrhea
and factors associated with the diagnosis among 3,578 low-income people with HIV
(PHIV) in the Ryan White Program Part A (RWP) in Miami-Dade County, Florida.
Methods: We used 2017 calendar year data from the Miami-Dade County RWP to
identify sociodemographic, behavioral, and clinical factors associated with a chlamydia
or gonorrhea diagnosis using logistic regression.
Results: About 49% of the 7,419 PHIV who were ≥18 years old in active Ryan White
care in 2017 reported being screened for chlamydia or gonorrhea. Of those screened,
2.3% were diagnosed with chlamydia, gonorrhea or both, with the highest prevalence
among those 18–39 years of age (4.9%) and men who have sex with men (3.1%). In the
adjusted model, compared to PHIV ≥40 years-old, PHIV aged 18–24 and 25–39 years
had higher odds of chlamydia or gonorrhea diagnosis (adjusted odds ratio [aOR] 4.36;
95% confidence interval [CI]: 1.76–10.82 and aOR 4.64; 95% CI; 2.66–8.12
respectively). Those with multiple sexual partners in the last 12 months had higher odds
of chlamydia or gonorrhea diagnoses (aOR 1.73; 95% CI; 1.07–2.79).
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Conclusions: Screening rates for chlamydia or gonorrhea are low, relative to CDC
guidelines, but prevalence is high. Interventions are needed to increase rates of screening
for these STIs. Moreover, targeted behavioral risk reduction techniques are highly
recommended among those 18–39 years of age and those who have multiple sexual
partners.
Keywords: Chlamydia, Gonorrhea, Predictors, Screening, HIV-infected
Introduction
Some sexually transmitted infections (STIs) are more common among people
with HIV (PHIV) compared with the general population without HIV (McClelland et al.,
2005). A systematic review conducted in 2011 examining STIs among PHIV in
developed and developing countries found that the median prevalence of an STI was
12.4% with the most commonly reported STIs being syphilis (9.5%), gonorrhea (9.5%),
chlamydia (5%), and trichomoniasis (18.8%) (Kalichman et al., 2011).
Sexually transmitted infections are risk factors for HIV transmission and
susceptibility (Patel et al., 2014). Sexually transmitted infections in PHIV increase the
risk of HIV transmission through HIV shedding, HIV replication, increase in viral
diversity, and through co-transmission of HIV with STIs (Galvin & Cohen, 2004).
Whether symptomatic or asymptomatic, presence of STIs among PHIV facilitates HIV
transmission (Kalichman et al., 2011). In addition, a new STI diagnosis may indicate
possible risky behaviors such as unprotected sex with an individual with an STI (Golden
et al., 2007; Erbelding et al., 2003). The Centers for Diseases Control and Prevention
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(CDC) recommends screening PHIV for STIs (syphilis, gonorrhea, chlamydia) at entry
into HIV treatment and at least annually thereafter during the course of HIV care
(Workowski & Bolan, 2015). CDC further recommends more frequent screening for STIs
depending on individual risk behaviors and the local epidemiology of STIs. Despite the
CDC recommendations, the rates of testing for STIs among PHIV are low (Flagg et al.,
2015; Quilter et al., 2017). Among sexually active PHIV in the Medical Monitoring
Project, the proportion tested annually for syphilis was 55%, gonorrhea 23% and
chlamydia 24% (Flagg et al., 2015).
Screening for STIs among PHIV is an important component of HIV care, and
early diagnosis and treatment of STIs has been suggested to reduce the rates of
transmission of HIV. Given the increased prevalence of chlamydia and gonorrhea among
PHIV and their risk of transmitting HIV, it is important to identify the associated factors
for more targeted management and prevention. Factors such as younger age (Lucar et al.,
2018; Ganesan et al., 2012; Rieg et al., 2008; Yang et al 2013; Do et al., 2001), lower
educational level (Singa et al., 2013), Hispanic ethnicity (Lucar et al., 2018; Ganesan et
al., 2012), men who have sex with men (MSM) ((Lucar et al., 2018; Yang et al 2013; Hu
et al., 2014), having more sexual partners (Kalichman et al., 2010), male gender, history
of hepatitis (Ganesan et al., 2012), being non-Hispanic Black (Yang et al 2013), fewer
than three years since HIV diagnosis, previous STI (Carpenter et al., 2013), higher CD4
cell count, and substance use (Rieg et al., 2008) were found to be associated with STI
diagnosis. In this study, the primary objective was to identify additional
sociodemographic, behavioral, and clinical factors associated with chlamydia and
gonorrhea diagnosis among PHIV in the Ryan White Program in Miami-Dade County.
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Methods
Population
Miami-Dade County Ryan White Program (RWP) Part A/ Minority AIDS
Initiative (MAI) data for the 2017 calendar year were used to identify sociodemographic,
behavioral, and clinical factors associated with chlamydia or gonorrhea diagnosis. The
RWP is supported by the Health Resources and Services Administration (HRSA) of the
U.S. Department of Health and Human Services to provide comprehensive HIV care,
essential support services, and medications for low-income people with HIV who are
uninsured and underserved. We included people who had received at least one medical
case management encounter or peer education support network service (and who had a
medical case manager-administered Comprehensive Health Assessment (CHA), our
source of data on screening, diagnoses and patient characteristics) in 2017. We excluded
PHIV who were less than 18 years of age in January 2017, out-of-network referrals in
2017 (people who were referred to the RWP from a non-RWP provider for ancillary
services only, and would, therefore, have no CHA) and those who died in 2017. We also
excluded people whose case was closed due to moving to another state/county, financial
ineligibility, or incarceration for greater than 6 months in 2017. Moreover, we excluded
people who had missing information on covariates (37 people had missing information on
sustained viral load suppression).

65

Independent variables, and outcome of interest
Our independent sociodemographic, behavioral, and clinical factors were obtained
from the patients’ self-reported CHA data, collected at time of entry into the RWP and biannually thereafter, and from laboratory results entered into the client's electronic case
management file (Table 1). A description of the sociodemographic, behavioral, and
clinical factors included in the analysis is given in Table 1. The annual chlamydia or
gonorrhea screening rate was obtained from the self-reported CHA (screened for
chlamydia in 2017 (yes/no) and screened for gonorrhea in 2017 (yes/no)). The outcome
of interest, chlamydia or gonorrhea diagnosis during the year 2017, was drawn from the
self-reported chlamydia and gonorrhea screening results on the CHA. A client was
considered to have a diagnosis of chlamydia or gonorrhea if he/she self-reported any
positive result during either of the bi-annual CHA interviews.
Data Analysis
We calculated annual chlamydia or gonorrhea screening rates for 2017 as the
number of RWP clients who reported receiving at least one test for chlamydia or
gonorrhea in 2017 (3578) divided by all PHIV 18 and over years old who are actively
enrolled in the RWP in the same year (7419). We calculated prevalence of chlamydia or
gonorrhea as the number of people who reported at least one positive result for chlamydia
or gonorrhea divided by the number of people who were screened in 2017. We conducted
descriptive analyses for the prevalence of chlamydia or gonorrhea to provide percentages
and frequencies of key parameters. Variables which were significant at p<0.1 in the
bivariate analysis were kept for the multivariable analysis. We estimated unadjusted and
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adjusted odds ratios with 95% confidence intervals (CI) to evaluate the association
between socioeconomic, behavioral and clinical factors and chlamydia or gonorrhea
diagnosis using a logistic regression model. All analyses were conducted using SAS
software V. 9.4 (SAS Institute Cary, NC).
Ethical Approval
This study was approved by Florida International University Institutional Review
Board.
Results
Of those 7419 PHIV actively enrolled in case management in the RWP in 2017, a
total of 3578 (48.7%) reported being screened for chlamydia or gonorrhea. The mean age
of the screened population was 44 years (SD 11.14). The majority of the participants
were males (82.3), foreign born (72.5%), Hispanic (65.7%), household income ≥100% of
the Federal Poverty Level (FPL) (65.2%), and ≥40 years of age (63.1%), (Table 2). Of
those screened, 82 (2.3%) reported at least one positive test for chlamydia or gonorrhea.
Of those, 39 had chlamydia only, 33 had gonorrhea, and 10 had both. All gonorrhea cases
were reported among males. The highest percent of chlamydia or gonorrhea was reported
among people who reported problematic alcohol use (7.0%), were aged 18–39 (4.9%),
had more than one sexual partner in the last 12 months (4.6%), reported unprotected sex
(3.8%), and were MSM (3.1%).
In the bivariate analysis (Table 2), chlamydia or gonorrhea diagnoses were
significantly associated with being aged 18–39 (p-value <0.001), being male (p-value
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<0.05), being men who have sex with men (p-value <0.05), not self-identifying as Haitian
(p-value <0.05), living alone (p-value <0.05), not being diagnosed with AIDS as of 2017
(p-value <0.05), reporting problematic alcohol use (p-value <0.05), being sexually active
(p-value <0.05), reporting more than one sexual partner in the last 12 months (p-value
<0.001), and reporting unprotected sex (p-value <0.05). In a full of model containing
variables that were significantly associated with chlamydia or gonorrhea in bivariate
analyses, age group and having more than one sexual partner in the last 12 months were
significantly associated with chlamydia or gonorrhea diagnoses (Table 3). Compared to
those aged 40 years and older, those aged 18–24 and those aged 25–39 were more likely
to report chlamydia or gonorrhea diagnosis (adjusted odds ratio [aOR] 4.36; 95%
confidence interval [CI]: 1.76–10.82 and aOR 4.64; 95% CI; 2.66–8.12 respectively).
Those who had more than one sexual partner during the last 12 months had higher odds
of chlamydia or gonorrhea diagnosis report (aOR 1.73; 95% CI; 1.07–2.79) compared to
those who did not.
Discussion and Conclusion
In this study, we report factors associated with a chlamydia or gonorrhea
diagnosis among a cohort of PHIV in the RWP Part A/MAI in Miami Dade County.
Results indicate that, of those enrolled in the RWP in 2017, less than half (48.7%) were
screened for chlamydia or gonorrhea. Of those screened for chlamydia or gonorrhea,
2.3% were diagnosed with chlamydia or gonorrhea, or both, with the highest prevalence
being among those 18–39 years of age and those who are MSM. We found that being
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aged 18–24, aged 25–39, and having multiple sexual partners in the last 12 months were
significant predictors of chlamydia or gonorrhea diagnosis reports.
Although the primary objective of this study was to assess the predictors of
chlamydia or gonorrhea diagnosis, we also estimated chlamydia or gonorrhea screening
to improve our understanding of the findings. Our results were consistent with findings of
previous studies (Flagg et al., 2015; Quilter et al., 2017), receipt of chlamydia or
gonorrhea screening was found to be suboptimal in our study. CDC recommends
screening sexually active individuals, at first HIV evaluation, and at least annually
thereafter during the course of HIV care (Workowski & Bolan, 2015). Previous studies
found that health care providers adhere to recommendations for syphilis screening but
conduct suboptimal chlamydia and gonorrhea screening (Carter et al., 2014; Barbee et al.,
2015).21,22 Obstacles that prevent routine chlamydia and gonorrhea screening may include
time constraints, difficulty obtaining a sexual history, language and cultural barriers,
patient confidentiality, patient reluctance, lack of comfort discussing sexual history with
provider and concerns about provider judgment (Quilter et al., 2017; Carter et al., 2014;
Barbee et al., 2015). Interventions, such as adoption of standard STI testing protocols,
promoting culturally sensitive risk assessment skills and tools, patient-driven health
service models that promote self-assessment, and creating an alert system in electronic
medical records may increase the proportion of people screened for STI (Flagg et al.,
2015; Barbee et al., 2015).
Prevalence of STIs is increasing in the general population (Centers for Disease
Control and Prevention, 2018) and among PHIV (Taylor et al., 2013; Skinner et al.,
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20140. In our study, about 2% of those screened were positive for either chlamydia or
gonorrhea, and 10 (12%) of those screened had both chlamydia and gonorrhea. The
prevalence of chlamydia or gonorrhea in our study is high compared to the prevalence in
the general population, but it is low compared to other studies conducted among PHIV. In
District of Columbia, during a median follow-up time of 32.5 months, Lucar et al found
4% of participants were diagnosed with chlamydia, and 3% were diagnosed with
gonorrhea (Lucar et al., 2018). In our study, high risk groups might not be screened, or
patients might not have reported chlamydia or gonorrhea test results diagnosed elsewhere
as reported in another study (Whitlock et al., 2011). Moreover, chlamydia or gonorrhea
diagnosis was self-reported, and the prevalence might be underestimated due to recall
bias or social desirability bias. Patients may also be reluctant to report STI diagnosis or
may be afraid to share the information. Florida law requires people with HIV and STI to
disclose their HIV status to their sexual partners (The Center for HIV Law and Policy,
n.d). The law declares that, “It is unlawful for any person who has chancroid, gonorrhea,
granuloma inguinale, lymphogranuloma venereum, genital herpes simplex, chlamydia,
nongonococcal urethritis (NGU), pelvic inflammatory disease (PID)/acute salpingitis, or
syphilis, when such person knows he or she is infected with one or more of these diseases
and when such person has been informed that he or she may communicate this disease to
another person through sexual intercourse, to have sexual intercourse with any other
person, unless such other person has been informed of the presence of the sexually
transmissible disease and has consented to the sexual intercourse (The Center for HIV
Law and Policy, n.d).”
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In agreement with previous studies (Lucar et al., 2018; Carpenter et al., 2013),
after controlling for covariates, our study found higher odds of chlamydia or gonorrhea
diagnosis among PHIV aged 18–39 and those having multiple sexual partners in the last
12 months. Problematic alcohol use was significant in the bivariate analysis, but the
association was attenuated in the multivariate analysis. Contrary to our expectation, being
MSM was not a significant predictor of chlamydia or gonorrhea diagnosis in our study,
although prevalence was high in this group. This likely may explain the inclusion of more
proximal determinants of STI in our model such as number of sexual partners. To test for
the presence of more proximal factors in our model, we conducted a post-hoc analysis.
After we excluded being sexually active and having more than one sexual partner from
the model, being MSM became significant at p-value <0.05. Thus, sexual activity might
be explaining the pathway through which MSM predicts chlamydia or gonorrhea
diagnosis. Our results didn’t show any significant association between sustained viral
suppression and prevalence of chlamydia or gonorrhea. People with HIV who are on
ART and have a sustained viral load may perceive that they have lower risk of HIV or
STI transmission and may increase their risky sexual activity (Ostrow et al., 2002).
Contrary to this hypothesis, sustained viral suppression was not significantly associated
with chlamydia or gonorrhea infection in our bivariate and multivariate analysis. We
conducted bivariate analysis for the predictors of chlamydia and gonorrhea diagnosis
separately. The association between sociodemographic, behavioral, and clinical factors
and each outcome was similar except for problematic alcohol use. Problematic alcohol
use was significant for gonorrhea diagnosis (p-value<0.05) but not for chlamydia
diagnosis. We had insufficient sample size to test for the association among other factors.
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There are limitations to consider when interpreting our ﬁndings. First, our study
depended on self-reported chlamydia or gonorrhea diagnosis among PHIV and thus may
be underreported. But studies have shown that self-reported STI diagnosis is a reliable
measure (Niccolai et al., 2005; Fisher et al., 2007). Second, the screening rate for
chlamydia or gonorrhea in 2017 was also self-reported. The rate may be underreported
because patients may not be informed about STI screenings when a doctor conducts the
annual screening. Third, we were not able to conduct stratified analyses by sex assigned
at birth because we had insufficient numbers of chlamydia or gonorrhea diagnoses among
females. But in a post-hoc analysis, we assessed the sociodemographic, behavioral and
clinical predictors of chlamydia or gonorrhea diagnosis among males. The results of the
final model were similar to the results of the final multivariate model among the general
population. Fourth, our analysis didn’t include significant proximate predictors of STIs
such as participants’ sexual networks, levels of alcohol used, and alcohol/drug use before
or during sex. These factors could be better predictors of chlamydia or gonorrhea
diagnosis. Finally, our measurements for sexual activity (“Are you sexually active?”) and
depression/anxiety (“Have you been feeling depressed or anxious?”) are subjective
measurements, and validated scales were unavailable in the dataset.
In summary, our results highlight the importance of regular screening among
PHIV. Screening for chlamydia or gonorrhea is suboptimal and prevalence is high among
PHIV. People aged 18–24 and 25–39 and those who have multiple sexual partners in the
last 12 months had increased chlamydia or gonorrhea diagnosis. Therefore, there is a
need for targeted behavioral risk reduction techniques among those groups to reduce STI
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transmission and subsequently HIV transmission. In addition, interventions are required
to increase the proportion of population screened for chlamydia or gonorrhea.
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Tables and figures
Table 1. Operational definition and categorization of variables
Name of variable
Definition and/or categorization
Age in 2017
18–24, 25–39 and ≥40 years
Sex assigned at birth
Male, Female
Men who have sex with
Yes, No
men
United States born
Yes, No
Race
Black, White/other
Other includes Asian, Native American/Alaskan Native,
Native Hawaiian/Pacific Island
Hispanic ethnicity
Yes, No
Haitian
Yes, No
Federal poverty level
Yes, No
(FPL) <100%
Federal poverty level <100% was defined as having a
household income less than $11,880 for a single person.19
Currently working
Yes, No
Household size
1=One person, 2=More than one person
Homelessness
Yes, No
A person was categorized as homeless if he/she reported a
non-permanent (includes homeless, transient, or transitional)
living arrangement
CDC-defined AIDS status Yes, No
as of 2017
Sustained viral load in
Yes, No
2017
Sustained viral suppression was defined as having a HIV
viral load <200 copies/ml in all viral load tests in 2017. For
people who had only 1 viral load measurement in 2017 (or
had at least 2 viral load measurements less than 3 months
apart) and the test showed viral suppression, we included the
last viral load test in 2016 in an effort to assess consistent
viral load suppression on at least 2 tests.20
Do you smoke?
Yes, No
History of injection drug
Yes, No
use (IDU)
A patient was considered to have a history of IDU if (a)
he/she has responded “Yes” to the question “Have you ever
injected drugs?” Or (b) reported “IDU” or “IDU and male to
male sexual intercourse” as mode of HIV transmission.
Problematic alcohol/drug Yes, No
use resulting in any
Problematic alcohol/drug use was derived from three
problem in daily activity
questions namely; (a) Has alcohol/drug use resulted in
or legal issue or
hazardous situation, (b) Has alcohol/drug use resulted in
hazardous situation
legal problems (c) Is your alcohol/drug use preventing you
from carrying out your daily activities?
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Feeling depressed or
anxious?

Yes, No
Feeling depressed or anxious was assessed based on a
question: “Have you been feeling depressed or anxious?”
Yes, No
Yes, No
Yes, No

Do you have a partner?
Are you sexually active?
Having more than one
sexual partner in the last
12 months
Do you use protection
Yes, No
during sexual intercourse? Those who have never used protection and those who
sometimes use protection were categorized as “No,” whereas
those who didn’t report any sexual activity, or those who
reported to use protection always, were categorized as
“Yes”.
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Table 2. Distributions of socioeconomic, behavioral and clinical factors and their
relationships with chlamydia or gonorrhea diagnoses among PHIV who reported
chlamydia or gonorrhea screening in the Ryan White program in Miami-Dade County in
2017 (N=3578)
Characteristics

Age in 2017
18–24
25–39
≥40
Sex assigned at birth
Male
Female
Men who have sex with men
Yes
No
US born
Yes
No
Race
White/other**
Black
Hispanic ethnicity
Yes
No
Haitian ethnicity
Yes
No
Federal poverty level <100%
Yes
No
Currently working
Yes
No
Household size
1 person
>1 person
Homeless
Yes
No
CDC-defined AIDS as of 2017
Yes
No
Sustained viral load
Yes
No

Total
population
N
3578

Positive for chlamydia or
gonorrhea
Yes
No
n (%)
n (%)
82 (2.3)
3533 (97.7)

p-value*

<0.001
151
1168
2259

7 (4.6)
57 (4.9)
18 (0.8)

144 (95.4)
1111 (95.1)
2241 (99.2)

2945
635

77 (2.6)
5 (0.8)

2866 (97.4)
630 (99.2)

2301
1277

71 (3.1)
11 (0.9)

2230 (96.9)
1266 (99.1)

984
2594

28 (2.8)
54 (2.1)

956 (97.2)
2540 (97.9)

2514
1064

63 (2.5)
19 (1.8)

2451 (97.5)
1045 (98.2)

2351
1227

57 (2.4)
25 (2.0)

2294 (97.6)
1202 (98.0)

311
3267

2 (0.6)
80 (2.5)

309 (99.4)
3187 (97.5)

<0.05

<0.001

0.173

0.188

0.453

<0.05

0.901
1245
2333

28 (2.3)
54 (2.3)

1217 (97.8)
2279 (97.7)

2391
1224

61 (2.5)
21 (1.7)

2330 (97.5)
1203 (98.3)

0.110

<0.05
2938
640

77 (2.6)
5 (0.8)

2861 (97.4)
635 (99.2)

146
3432

2 (1.4)
80 (2.3)

144 (98.6)
3352 (97.7)

0.447

<0.05
1227
2351

15 (1.2)
67 (2.8)

1212 (98.8)
2284 (97.2)

536
3042

12 (2.2)
70 (2.3)

524 (97.8)
2972 (97.7)

0.929
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Smoking
0.663
Yes
449
9 (2.0)
440 (98.0)
No
3129
73 (2.3)
3056 (97.7)
History of injection drug use
0.617
Yes
137
4 (2.9)
133 (97.1)
No
3441
78 (2.3)
3363 (97.7)
Problematic alcohol use
<0.05
Yes
57
4 (7.0)
53 (93.0)
No
3521
78 (2.2)
3443 (97.8)
Feeling depressed/anxious
0.970
Yes
485
11 (2.3)
474 (97.7)
No
3093
71 (2.3)
3022 (97.7)
Have a partner
0.529
Yes
1450
36 (2.5)
1414 (97.5)
No
2128
46 (2.2)
2082 (97.8)
Sexually active
<0.05
Yes
2437
69 (2.8)
2368 (97.2)
No
1141
13 (1.1)
1128 (98.9)
Had more than one sexual partner
<0.001
in the last 12 months
Yes
884
41 (4.6)
843 (95.4)
No
2694
41 (1.5)
2653 (98.5)
Unprotected sex
<0.05
Yes
3181
67 (2.1)
3114 (97.9)
No
397
15 (3.8)
382 (96.2)
US: United States; CDC: Centers for Diseases Control and Prevention; AIDS: Acquired Immune
Deficiency Syndrome
*p-values for the Chi-square test or Fisher exact test
**Other includes Asian (11), Native American/Alaskan Native (6), Native Hawaiian/Pacific
Island (3)
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Table 3 Unadjusted and adjusted odds ratio for the association between socioeconomic,
behavioral and clinical factors, and chlamydia or gonorrhea diagnosis
Characteristics
Age in 2017
18–24
25–39
≥40
Sex assigned at birth
Male
Female
Men who have sex with
men
Yes
No
US born
Yes
No
Race
White/other
Black
Hispanic ethnicity
Yes
No
Haitian
Yes
No
Federal poverty level
<100%
Yes
No
Currently working
Yes
No
Household size
1 person
>1 person
Homeless
Yes
No
CDC-defined AIDS as of
2017
Yes
No
Sustained viral load
Yes
No
Smoking
Yes
No

Unadjusted OR

Adjusted OR

6.05 (2.49–14.72)
6.39 (3.74–10.90)
Ref

4.36 (1.76–10.82)
4.64 (2.66–8.12)
Ref

3.38 (1.36–8.40)
Ref

1.06 (0.32–3.52)
Ref

p-value*
<0.001

0.923

0.249
3.66 (1.93–6.94)
Ref

1.68 (0.70–3.91)
Ref

1.38 (0.87–2.19)
Ref

–
–

Ref
0.71 (0.42–1.19)

–
–

Ref
0.84 (0.52–1.35)

–
–

0.26 (0.06–1.05)
Ref

0.72 (0.17–3.14)
Ref

0.97 (0.61–1.54)
Ref

–

Ref
0.68 (0.41–1.12)

–
–

3.42 (1.38–8.48)
Ref

1.93 (0.74–5.00)
Ref

0.58 (0.14–2.39)
Ref

–

0.665

0.176

0.406
0.42 (0.24–0.74)
Ref

0.78 (0.43–1.41)
Ref

Ref
1.03 (0.55–1.91)

–
–

0.86 (0.43–1.72)
Ref

–
–
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History of injection drug
use
Yes
1.30 (0.47–3.60)
–
No
Ref
Problematic alcohol use
0.077
Yes
3.33 (1.18–9.43)
2.67 (0.90–7.96)
No
Ref
Ref
Feeling depressed/anxious
Yes
0.99 (0.52–1.88)
–
No
Ref
–
Have a partner
Yes
Ref
–
No
0.87 (0.56–1.35)
–
Sexually active
0.158
Yes
2.53 (1.39–4.59)
1.58 (0.84–3.00)
No
Ref
Ref
Had more than one sexual
<0.05
partner in the last 12
months
Yes
3.15 (2.03–4.89)
1.73 (1.07–2.79)
No
Ref
Ref
Unprotected sex
0.634
Yes
Ref
Ref
No
1.83 (1.03–3.23)
0.86 (0.47–1.59)
US: United States; CDC: Centers for Diseases Control and Prevention; AIDS: Acquired Immune
Deficiency Syndrome
*p-values for the Wald Chi-square test of the multivariate model
The multivariate model included factors related to the outcome at p<0.1
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CONCLUSIONS
In this dissertation project, we developed risk prediction tools to identify PHIV
who are at risk of non-retention in HIV care and non-viral suppression; and identified
predictors of chlamydia or gonorrhea among PHIV.
The first study developed a risk prediction tool to identify PHIV at risk of nonretention in care (defined as having evidence of at least two occurrences of any
combination of (a) face-to-face encounter(s) with a Ryan White Program medical care
professional, or (b) laboratory tests (CD4 or viral load), at least three months apart during
the follow-up year). We found that about 24% of the population were not retained in care
in the follow-up year. The risk prediction tool included six factors: age group, race,
poverty level, homelessness, problematic alcohol/drug use and viral suppression status.
The risk prediction tool had a total score ranging 0 to 17. A cutoff value of 5 in the risk
score had a sensitivity of 38% and a specificity of 84%. Moreover, those who were in the
high risk (fourth quartile) were about 5 times as likely not to be retained in care compared
with those who were in the low risk (first quartile).
The risk prediction tool for non-retention in care had low discrimination (cstatistic=0.65). In order to improve the discrimination, future risk prediction tools should
include better predictive factors in the model. Although they may not be routinely
accessible, information about factors such as sexually transmitted infections, adherence to
medications, prior treatment failure, previous appointment attendance, and other unmet
needs could improve discrimination of the model. This risk prediction tool can be used in
situations where these additional variables are not available.
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The second study developed a risk prediction tool for PHIV who are at risk of not
achieving viral suppression (defined as having viral load ≥200 copies/mL in the last viral
load measurement in the follow-up year). About 9% of the population was not virally
suppressed in the follow-up year. The risk prediction tool for non-viral suppression
included seven factors: age group, race, poverty level, AIDS diagnosis, homelessness,
problematic alcohol/drug use, and viral suppression status. The risk prediction tool had
good discriminative ability (c-statistic=0.77) and a total score ranging 0 to 26. A cutoff
point of 7 in the risk score had a sensitivity of 63%, specificity of 77%, positive
predictive value of 21% and negative predictive value of 95%. The cutoff point 7
identiﬁed 62% of individuals who failed to achieve viral suppression in next year by
putting 26.8% of our population for intervention. Based on the distribution of the total
risk score, those in the high-risk category (score 8-26) had about 23 times the risk of
having non-viral suppression compared to the low-risk (score 0-1) group. The tool needs
external validation in order to assess the performance of the model in other populations.
The factors included in the risk prediction tools can be easily obtained from
medical records or by interviewing the patient and can be implemented in a variety of
settings. Most of the factors in both risk prediction tools are similar, except the risk
prediction tool for non-viral suppression additionally includes the factor AIDS diagnosis.
Being diagnosed with AIDS could be a risk factor for being non-viral suppression due to
the advanced stage of the disease.
We created an easy-to-use tool for both outcomes. The tools include the risk
factors with their corresponding risk scores. The tool also includes the probabilities
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associated with each total risk score. Clinicians and healthcare providers can use these
tools to calculate the total risk score and the corresponding risk of non-retention in care
or non-viral suppression of a patient. These risk prediction tools can identify high-risk
individuals who could benefit from any available interventions.
The third study assessed the prevalence of self-reported chlamydia or gonorrhea
and factors associated with these self-reported diagnoses among PHIV. We found that
about 49% of the PHIV reported that they were screened for chlamydia or gonorrhea
during 2017. Relative to the CDC recommendations, this screening rate is low. Of those
screened, 2.3% reported that they were diagnosed with chlamydia, gonorrhea or both.
The highest prevalence of chlamydia or gonorrhea was among those 18–39 years of age
(4.9%) and men who have sex with men (3.1%). In the multivariate model, compared to
those ≥40 years-old, those 18–39 years-old had higher odds of self-reported chlamydia or
gonorrhea diagnosis. Moreover, those who had multiple sexual partners in the last 12
months had increased odds of chlamydia or gonorrhea diagnosis. Our results highlight the
importance of interventions to increase the proportion of population screened for
chlamydia or gonorrhea. Moreover, targeted behavioral risk reduction techniques are
recommended for those 18–39 years of age and those who have multiple sexual partners
to reduce STI transmission and subsequently HIV transmission.
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